Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.
|Articles|August 17, 2012
Survey: Few ACOs Ready For Financial Risk
Advertisement
Few hospitals interested in becoming accountable care organizations are ready to take on financial risk, according to a
“We’re really still at the very beginning of the adoption curve of the ACO model,” says lead author Anne-Marie Audet, who researches health system quality and efficiency at Commonwealth. “The challenge is that hospitals are still not ready to assume financial risk.”
Read the full story:
Source: Kaiser Health News
Advertisement
Related to this article
FDA approved belzutifan plus lenvatinib for advanced ccRCC after PD-1/PD-L1 therapy, expanding treatment options for those with disease progression.
A 3-year registry found dupilumab controlled atopic dermatitis (AD) in most children, though those under 6 years were likelier to stop treatment.
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.
Topical ruxolitinib prescribing in Medicare Part D surged through 2024, but its cost per day runs 16 times higher than generic tacrolimus.
Baseline biopsies separated 16 patients who later developed hepatocellular carcinoma from 32 matched controls a median 6.1 years ahead.
Advertisement
Advertisement
Trending on AJMC
1
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
2
Surrogate End Points, Drug Costs Complicate Oncology Formularies
3
Oncology Patients in Clinical Trials: A Health Care Cost Analysis
4
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
5